ストックスクリーナーアプリを入手
18.98
3.66%
0.67
アフターアワーズ：
19.15
0.17
+0.90%
Summit Therapeutics Inc (SMMT) 最新ニュース
Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
(SMMT) Trading Report - Stock Traders Daily
Here's Merck's $3.3 Billion Insurance Against Summit's Advance - Investor's Business Daily
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters
Has Summit Therapeutics Stock Already Peaked? - AOL
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
2 Hot Biopharma Stocks to Buy and Hold for 5 Years - AOL
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga
Is Summit Therapeutics a Millionaire Maker? - AOL
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Why Summit Therapeutics Stock Was a Winner Today - MSN
Trading (SMMT) With Integrated Risk Controls - Stock Traders Daily
SMMT Surges as Analyst Initiates Coverage with Buy Rating - GuruFocus.com
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Yahoo Finance UK
Summit Therapeutics Leads the Parade of Big Gainers - GuruFocus.com
Summit Therapeutics shares rated Market Outperform by JMP Securities - Investing.com UK
Summit Therapeutics Leads The Parade Of Big Gainers - Forbes
Summit Therapeutics (NASDAQ:SMMT) Earns Market Outperform Rating from Analysts at JMP Securities - MarketBeat
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - MSN
3 Magnificent Stocks Under $100 to Buy in November - The Motley Fool
abrdn plc Invests $24.89 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
H.C. Wainwright cuts Summit Therapeutics stock target, maintains Buy amid study expansion - Investing.com Canada
Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com
Summit Therapeutics (NASDAQ:SMMT) Price Target Cut to $44.00 by Analysts at HC Wainwright - MarketBeat
Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2024 Earnings Call Transcript - Insider Monkey
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales - Yahoo Finance
Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Summit Therapeutics reports Q3 EPS (5c), consensus (7c) - MSN
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus.com
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight - Yahoo Finance
Summit Therapeutics Advances NSCLC Trials and Strengthens Financials - TipRanks
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 10.4%What's Next? - MarketBeat
Summit Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 - BioSpace
China Universal Asset Management Co. Ltd. Purchases 56,879 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Tesla, Xpeng, Summit Therapeutics lead Monday's morning market cap stock movers - Investing.com Australia
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - StockTitan
Summit Therapeutics Inc. (SMMT): An Unstoppable Stock That Could Make You Richer - Insider Monkey
Billionaire Buys Miami Penthouse After His Firm’s 689% Stock Rally - MSN
8 Unstoppable Stocks That Could Make You Richer - Insider Monkey
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings? - MSN
1.45%
1.11%
大文字化:
|
ボリューム (24 時間):